HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ETS2
ETS proto-oncogene 2, transcription factor
Chromosome 21 · 21q22.2
NCBI Gene: 2114Ensembl: ENSG00000157557.14HGNC: HGNC:3489UniProt: P15036
145PubMed Papers
20Diseases
0Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
OncogeneTranscription Factor
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
positive regulation of transcription by RNA polymerase IInucleusprotein bindingprotein domain specific bindingtype 2 diabetes mellitusplacenta praeviadiabetes mellituseye disease
✦AI Summary

ETS2 is a transcription factor that binds the GGAA/T core motif in gene promoters to regulate transcription through RNA polymerase II 1. As a founding member of the ETS family, ETS2 functions as a master regulator of macrophage-driven inflammation, with genetic variants on chromosome 21 causally linked to inflammatory bowel disease, ankylosing spondylitis, and primary sclerosing cholangitis 2. ETS2 overexpression in macrophages upregulates multiple inflammatory cytokines including TNF and IL-23, and genes regulated by ETS2 are enriched for inflammatory bowel disease GWAS hits 2. Beyond inflammation, ETS2 is phosphorylated by Erk1/2 kinase and cooperates with NFAT transcription factor to drive cardiac hypertrophy by activating hypertrophic marker genes and microRNA-223 3. In antiviral immunity, ETS2 is phosphorylated by TAOK1 kinase downstream of oxaloacetate sensing and promotes type I interferon responses critical for influenza defense 4. ETS2 demonstrates context-dependent roles in cancer, acting as either tumor suppressor or oncogene 1, and cooperates with mutant p53 to promote transformation 5. In glioblastoma, the ID2-ETS2 axis regulates pro-tumoral microglia phenotype acquisition 6. ETS2 represents a promising therapeutic target for inflammatory diseases, though direct inhibition presents challenges 7.

Sources cited
1
ETS2 is causally linked to inflammatory bowel disease, ankylosing spondylitis, and primary sclerosing cholangitis; functions as master regulator of inflammatory macrophages; upregulates TNF and IL-23
PMID: 38839969
2
ETS2 is phosphorylated by Erk1/2 and cooperates with NFAT to regulate hypertrophic genes including ANP, BNP, Rcan1.4, and microRNA-223 in cardiac hypertrophy
PMID: 33821668
3
ETS2 is phosphorylated by TAOK1 kinase downstream of oxaloacetate sensing and supports TBK1 expression for type I interferon responses against influenza
PMID: 40983701
4
ETS2 is a founding ETS family transcription factor with context-dependent tumor suppressive or oncogenic functions in cancer; binds DNA promoters to regulate target genes
PMID: 40490201
5
ETS2 functions as master regulator of macrophage inflammation upregulating TNFα, IL-23, IL1β; represents potential therapeutic target despite challenges of direct inhibition
PMID: 40227609
6
ETS2 regulates NF-κB and JAK-STAT pathways, affects epithelial barrier function and tight junction proteins, with genetic variants associated with IBD susceptibility
PMID: 40922284
7
Mutant p53 forms complex with ETS2 that promotes cancer through gain-of-function activities
PMID: 26925389
8
ID2-ETS2 axis regulates transcriptional acquisition of pro-tumoral microglia phenotype in glioblastoma
PMID: 39019900
Disease Associationsⓘ20
type 2 diabetes mellitusOpen Targets
0.40Moderate
placenta praeviaOpen Targets
0.34Weak
diabetes mellitusOpen Targets
0.33Weak
eye diseaseOpen Targets
0.29Weak
tuberculosisOpen Targets
0.29Weak
osteoarthritis, hipOpen Targets
0.26Weak
open-angle glaucomaOpen Targets
0.24Weak
total hip arthroplastyOpen Targets
0.24Weak
Hallux valgusOpen Targets
0.23Weak
alopecia areataOpen Targets
0.22Weak
heart diseaseOpen Targets
0.18Weak
skin woundOpen Targets
0.16Weak
osteoarthritisOpen Targets
0.14Weak
aortic aneurysmOpen Targets
0.14Weak
Abnormality of the skeletal systemOpen Targets
0.13Weak
bone fractureOpen Targets
0.11Weak
osteoporosisOpen Targets
0.11Weak
neoplasmOpen Targets
0.10Weak
prostate carcinomaOpen Targets
0.10Weak
hypertensionOpen Targets
0.10Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Related Genes
TP53Protein interaction100%JUNProtein interaction100%MAPK3Protein interaction99%FOSProtein interaction99%GATA1Protein interaction98%RUNX1Protein interaction98%
Tissue Expression6 tissues
Liver
100%
Lung
85%
Bone Marrow
54%
Brain
39%
Ovary
31%
Heart
21%
Gene Interaction Network
Click a node to explore
ETS2TP53JUNMAPK3FOSGATA1RUNX1
PROTEIN STRUCTURE
Preparing viewer…
PDB4MHV · 2.45 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.43Moderately Constrained
pLIⓘ
1.00Intolerant
Observed/Expected LoF0.27 [0.17–0.43]
RankingsWhere ETS2 stands among ~20K protein-coding genes
  • #3,132of 20,598
    Most Researched145 · top quartile
  • #2,343of 17,882
    Most Constrained (LOEUF)0.43 · top quartile
Genes detectedETS2
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
A disease-associated gene desert directs macrophage inflammation through ETS2.
PMID: 38839969
Nature · 2024
1.00
2
Cooperative Binding of ETS2 and NFAT Links Erk1/2 and Calcineurin Signaling in the Pathogenesis of Cardiac Hypertrophy.
PMID: 33821668
Circulation · 2021
0.90
3
Oxaloacetate sensing promotes innate immune antiviral defence against influenza virus infection.
PMID: 40983701
Nat Microbiol · 2025
0.80
4
Deciphering ETS2: An indispensable conduit to cancer.
PMID: 40490201
Biochim Biophys Acta Rev Cancer · 2025
0.70
5
The Role of ETS2 in Macrophage Inflammation.
PMID: 40227609
DNA Cell Biol · 2025
0.60